Agios Pharmaceuticals reported $0 in Gross Profit on Sales for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Alexion Pharmaceuticals ALXN:US $ 1299.7M 33.4M
Alnylam Pharmaceuticals ALNY:US $ 104.06M 20.02M
Amgen AMGN:US $ 4718M 70M
AstraZeneca AZN:LN 5.22B 90M
Bayer BAYN:GR 603.6M 215.3M
Biogen BIIB:US $ 2927M 343.5M
Biomarin Pharmaceutical BMRN:US $ 331.52M 59.18M
Bluebird Bio BLUE:US $ 19.73M 17.65M
Bristol Myers Squibb BMY:US $ 7454M 326M
Daiichi Sankyo 4568:JP Y 154736M 16901M
Eli Lilly And LLY:US $ 4277.4M 367.3M
Exelixis EXEL:US $ 250M 33M
Gilead Sciences GILD:US $ 4079M 500M
GlaxoSmithKline GSK:LN 519.5M 111.4M
JAZZ PHA JAZZ:US $ 558.79M 24.36M
Merk MRK:US $ 7738M 1075M
Novartis NOVN:VX 8.28B 868M
Novartis NVS:US $ 8970M 685M
Pfizer PFE:US $ 9569M 113M
Puma Biotechnology PBYI:US $ 61M 19M
Regeneron Pharmaceuticals REGN:US $ 1676.5M 65.6M
Sarepta Therapeutics SRPT:US $ 124M 23M
Seattle Genetics SGEN:US $ 983.44M 753.68M
Vertex Pharmaceuticals VRTX:US $ 1339.96M 12.64M
YTE INCY:US $ 660.08M 113.49M